Please assess the completion status of the following clinical trial:

Trial Title: Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Competent adult English speaking subjects~* With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis,~* With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction,~* With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin~Exclusion Criteria:~* Subjects who do not meet the inclusion criteria~* Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with limited stage SCLC (Type: EXPERIMENTAL): Subjects with limited stage SCLC treated sequentially with cisplatin.
- Historical Controls (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).